Articles

Find an Article

Filter articles

Showing 1 to 10 of 712 results

UK experimental use exemptions: Part 2—the Bolar exemption

UK22-07-2021Sophie Topham

In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.

UK experimental use exemptions: part 1—the original

15-07-2021Sophie Topham

In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

Conference preview: ACI breaks down Section 337 at the 13th Annual Practitioners’ Think Tank

International23-06-2021The C5 Group (American Conference Institute, The Canadian Institute, C5)

Making sense of the newest Section 337 developments will be a key focus of The American Conference Institute’s 13th Annual Practitioners’ Think Tank on ITC Litigation and Enforcement.

Navigating patent eligibility in digital healthcare

US22-06-2021Linda Thayer, Aaron Capron and Sneha Nyshadham

Patent applicants with digital health inventions need to remember that being useful and novel may not be enough, warn Linda Thayer, Aaron Capron and Sneha Nyshadham of Finnegan, Henderson, Farabow, Garrett & Dunner.

The curious case of Wuhan’s Institute of Virology and remdesivir

China20-04-2021Thomas Moga

Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.

Sovereign immunity: a venue-dependent protection

US06-04-2021Simon Roberts, Nitya Anand and Eric Wang

A recent University of Texas dispute perfectly illustrates the differing role sovereign immunity takes in proceedings at the Patent Trial and Appeal Board and district court, say Simon Roberts, Nitya Anand and Eric Wang of Hogan Lovells.

EPO’s new examination guidelines: what you need to know

EU06-04-2021Clare Roskell and Samantha Moodie

The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

The uncertain future of antibody claims

US01-04-2021Benjamin Pelletier

Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.

Got a patent, now where to validate?

EU22-03-2021Sarah Kostiuk-Smith

For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.

Patent filing strategies for pharma startups

International16-03-2021Jian Siang Poh and Angus Fairbairn

Patents are a key asset for pharmaceutical startups, but where are they choosing to file? Jian Siang Poh and Angus Fairbairn of Marks & Clerk report.

Showing 1 to 10 of 712 results

LSIPR